BACKGROUND: Systemic mast cell activation disease (MCAD) is characterized by an increased and unregulated release of mast cell mediators which can evoke a multifaceted clinical picture often resembling irritable bowel syndrome or fibromyalgia. Because of the considerable prevalence (~ 17 %) of MCAD surgeons are frequently unwittingly confronted with MCAD patients in whom unexpected intraoperative and postoperative complications may occur. Therefore, knowledge of the particular requirements is of relevance for surgical treatment of MCAD patients. OBJECTIVE: The present paper outlines a concept of surgical treatment of MCAD patients based on the literature which is illustrated by a case report on emergency laparoscopic cholecystectomy. CONCLUSIONS: Due to the high prevalence of MCAD in the general population it can be assumed that the frequency in the surgical patient population is similar. If a patient has MCAD, specific characteristics should be taken into account in the surgical procedure to avoid increased operative and complication risks resulting from MCAD.
BACKGROUND: Systemic mast cell activation disease (MCAD) is characterized by an increased and unregulated release of mast cell mediators which can evoke a multifaceted clinical picture often resembling irritable bowel syndrome or fibromyalgia. Because of the considerable prevalence (~ 17 %) of MCAD surgeons are frequently unwittingly confronted with MCADpatients in whom unexpected intraoperative and postoperative complications may occur. Therefore, knowledge of the particular requirements is of relevance for surgical treatment of MCADpatients. OBJECTIVE: The present paper outlines a concept of surgical treatment of MCADpatients based on the literature which is illustrated by a case report on emergency laparoscopic cholecystectomy. CONCLUSIONS: Due to the high prevalence of MCAD in the general population it can be assumed that the frequency in the surgical patient population is similar. If a patient has MCAD, specific characteristics should be taken into account in the surgical procedure to avoid increased operative and complication risks resulting from MCAD.
Authors: Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe Journal: Int Arch Allergy Immunol Date: 2011-10-27 Impact factor: 2.749
Authors: Jürgen Homann; Ulrich W Kolck; Andreas Ehnes; Thomas Frieling; Martin Raithel; Gerhard J Molderings Journal: Med Klin (Munich) Date: 2010-09-08
Authors: Andreas Mazarakis; Constantinos M Koutsojannis; Nicholas G Kounis; Dimitrios Alexopoulos Journal: Acta Cardiol Date: 2005-06 Impact factor: 1.718
Authors: Kirsten Alfter; Ivar von Kügelgen; Britta Haenisch; Thomas Frieling; Alexandra Hülsdonk; Ulrike Haars; Arndt Rolfs; Gerhard Noe; Ulrich W Kolck; Jürgen Homann; Gerhard J Molderings Journal: Liver Int Date: 2008-07-23 Impact factor: 5.828
Authors: Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2016-04-30 Impact factor: 3.000